Back to discover
Disease

Insulinoma

Active therapeutic pipelineEmerging research
MeSHInsulinoma
2
Publications
14
Clinical trials
1
Related conditions
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials with recent milestones (1 completed or reporting results).
Clinical Milestones2View
Results posted 1
Other updates 1
Activity timeline2

Clinical trials

10 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
14
All trials
2
Active
0
Late-stage
6
Completed
Recently completed

Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors

Phase 2 · Completed · University of Southern California

A Phase 2 Study of Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Phase 2 · Completed · Shaheen Shagufta

A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer

Phase 2 · Completed · National Cancer Institute (NCI)

Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Phase 1 · Completed · National Cancer Institute (NCI)

A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma

Phase 2 · Completed · National Cancer Institute (NCI)

A Phase I Trial of Herceptin and Interleukin-12

Phase 1 · Completed · National Cancer Institute (NCI)

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
19932023
Major themes6
  • Gastrinoma1
  • Glucagonoma1
  • Insulinoma1
  • Neuroendocrine Tumors1
  • Pancreatic Neoplasms1
  • Receptors, Glucagon1
Leading journals2
  • Journal of neuroendocrinology1
  • The Journal of biological chemistry1
Leading researchers8
  • Bartsch DK1
  • Castaño JP1
  • Christ E1
  • Eng J1
  • Faggiano A1
  • Falconi M1
  • Fehmann HC1
  • Göke B1
Affiliations (unnormalised)6
  • Centre Hospitalier Annecy Genevois (CHANGE)1
  • Department of Clinical and Molecular Medicine1
  • Department of Oncology - OncoHealth Institute1
  • ENETS Centre of Excellence1
  • ENETS Centre of Excellence for Neuroendocrine and Endocrine Tumours1
  • Hospital Universitario Reina Sofía1

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Pancreatic Neoplasms2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA.

Identifiers
MeSHInsulinoma
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.